1. Thyroid hormone treatment alleviates the impairments of neurogenesis, mitochondrial biogenesis and memory performance induced by methamphetamine.
- Author
-
Seyedhosseini Tamijani SM, Beirami E, Ahmadiani A, and Dargahi L
- Subjects
- Animals, Behavior, Animal drug effects, Cognition drug effects, Cognition Disorders chemically induced, Cognition Disorders prevention & control, Cognition Disorders psychology, Doublecortin Protein, Hippocampus drug effects, Hippocampus metabolism, Inflammation chemically induced, Inflammation prevention & control, Male, Memory Disorders psychology, Psychomotor Performance drug effects, Rats, Rats, Wistar, Reelin Protein, Synapses drug effects, Thyroid Hormones blood, Thyroxine therapeutic use, Triiodothyronine therapeutic use, Central Nervous System Stimulants toxicity, Memory Disorders chemically induced, Memory Disorders prevention & control, Methamphetamine toxicity, Neurogenesis drug effects, Organelle Biogenesis, Thyroid Hormones therapeutic use
- Abstract
Chronic use of methamphetamine (MA), a neurotoxic psychostimulant, leads to long-lasting cognitive dysfunctions in humans and animal models. Thyroid hormones (THs) have several physiological actions and are crucial for normal behavioral, intellectual and neurological development. Considering the importance of THs in the cognitive processes, the present study was designed to evaluate the therapeutic effects of THs on cognitive and neurological impairments induced by MA. Escalating doses of MA (1-10 mg/kg, IP) were injected twice daily for 10 consecutive days in rats and cognitive functions were evaluated using behavioral tests. The expression of factors involved in neurogenesis (NES and DCX), mitochondrial biogenesis (PGC-1α, NRF-1, and TFAM), neuroinflammation (GFAP, Iba-1, and COX-2) as well as Reelin and NT-3 (synaptic plasticity and neurotrophic factor, respectively) was measured in the hippocampus of MA-treated animals. The effects of three different doses of T4 (20, 40 or 80 μg/kg; intraperitoneally) or T3 (20, 40 or 80 μg/rat; 2.5 μl/nostril; intranasal) treatment, once a day for one week after MA cessation, were assessed in MA-treated rats. After the last behavioral test, serum T4 and T3 levels were measured using radioimmunoassay. The results revealed that repeated escalating regimen of MA impaired cognitive functions concomitant with neurogenesis and synaptic plasticity impairments, mitochondrial dysfunction, and neuroinflammation. T4 or T3 treatment partially decreased the alterations induced by MA. These findings suggest that THs can be considered as potential candidates for the reduction of MA abuse related neurocognitive disturbances., (Copyright © 2019 Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF